Dilated cardiomyopathy: A tale of cytoskeletal proteins and beyond

Journal of Cardiovascular Electrophysiology

Volumn 17, Issue 8, 2006, Pages 919-926

  Towbin, Jeffrey A ^a,b   Bowles, Neil E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN;

AUTOSOMAL DOMINANT DISORDER; BECKER MUSCULAR DYSTROPHY; CONGESTIVE CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEART FAILURE; HEART HYPERTROPHY; HUMAN; INCIDENCE; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED DISORDER;

ANIMALS; CARDIOMYOPATHY, DILATED; CYTOSKELETAL PROTEINS; GENES, X-LINKED; HUMANS; MUTATION; SARCOMERES;

EID: 33746038182     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2006.00530.x     Document Type: Review

References (127)

1. Richardson P, McKenna W, Bristow M, et al: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-842.
2. Abelman WH, Lorrell BH: The challenge of cardiomyopathy. J Am Coll Cardiol 1989;13:1219.
3. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994;13:S107-S112.
4. Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC: Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2005;24:200-204.
5. Towbin JA, Bowles NE: The failing heart. Nature 2002;415:227-233.
6. Towbin JA: The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998;10:131-139.
7. Squire JM: Architecture and function in the muscle sarcomere. Curr Opin Struct Biol 1997;7:247-257.
8. Gregorio CC, Antin PB: To the heart of myofibril assembly. Trends Cell Biol 2000;10:355-362.
9. Vigoreaux JO: The muscle Z band: Lessons in stress management. J Muscle Res Cell Motil 1994;15:237-255.
10. Capetanaki Y: Desmin cytoskeleton: A potential regulator of muscle mitochondrial behaviour and function. Trends Cardiovasc Med 2002;12:339-348.
11. Stewart M: Intermediate filament structure and assembly. Curr Opin Cell Biol 1993;5:3-11.
12. Straub V, Campbell KP: Muscular dystrophies and the dystrophin- glycoprotein complex. Curr Opin Neurol 1997;10:168-175.
13. Nowak K, McCullagh K, Poon E, Davies KE: Muscular dystrophies related to the cytoskeleton/nuclear envelope. Novartis Found Symp 2005;264:98-111.
14. Cox GF, Kunkel LM: Dystrophies and heart disease. Curr Opin Cardiol 1997;12:329-343.
15. Guyon JR, Mosley AN, Zhou Y, O'Brien KF, Sheng X, Chiang K, Davidson AJ, Volinski JM, Zon LI, Kunkel LM: The dystrophin associated protein complex in zebrafish. Hum Mol Genet 2003;12: 601-615.
16. Kaprielian RR, Stevenson S, Rothery SM, Cullen MJ, Severs NJ: Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation 2000;101:2586-2594.
17. Meng H, Leddy JJ, Frank J, Holland P, Tuana BS: The association of cardiac dystrophin with myofibrils/Z-discs regions in cardiac muscle suggests a novel role in the contractile apparatus. J Biol Chem 1996;271:12364-12371.
18. Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO: Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res 1993;72:349-360.
19. Furukawa T, Ono Y, Tsuchiya H, et al: Specific interaction of the potassium channel beta-subunit minK with the sarcomeric protein T-cap suggests a T-tubule-myofibril linking system. J Mol Biol 2001;313:775-784.
20. Kucera JP, Rohr S, Rudy Y: Localization of sodium channels in intercalated disks modulates cardiac conduction. Circ Res 2002;91:1176-1182.
21. Ribaux P, Bleicher F, Couble ML, et al: Voltage-gated sodium channel (SkM1) content in dystrophin-deficient muscle. Pflugers Arch 2001;441:746-755.
22. Connors NC, Adams ME, Froehner SC, Kofuji P: The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. J Biol Chem 2004;279:28387-28392.
23. Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2007-2018.
24. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989;80:564-572.
25. Lipshultz SE, Sleeper LA, Towbin JA, et al: The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348:1647-1655.
26. Nugent AW, Danbeney PEF, Chondros P, et al: The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348:1639-1646.
27. Arola A, Touminen J, Ruuskanen O, Jokinen E: Idiopathic dilated cardiomyopathy in children: Prognostic indicators and outcome. Pediatrics 1998;101:369-376.
28. Kannel WB: Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167-173.
29. Berko BA, Swift M: X-linked dilated cardiomyopathy. N Engl J Med 1987;316:1186-1191.
30. Towbin JA, Hejtmancik JF, Brink P, et al: X-linked dilated cardiomyopathy (XLCM): Molecular genetic evidence of linkage to the Duchenne muscular dystrophy gene at the Xp21 locus. Circulation 1993;87:1854-1865.
31. Muntoni F, Cau M, Ganau A, et al: Brief report: Deletion of the dystrophin muscle-specific promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329:921-925.
32. Milasin J, Muntoni F, Severini CM, et al: A point mutation in the 5′ splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet 1996;5:73-79.
33. Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA: Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation 1997;95:2434-2440.
34. Ferlini A, Galie N, Merlini L, et al: A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet 1998;63:436-460.
35. Yoshida K, Nakamura A, Yazak M, et al: Insertional mutation by transposable element, L1, in the DMD gene results in X-linked dilated cardiomyopathy. Hum Molec Med 1998;7:1129-1132.
36. Franz W-M, Muller M, Muller AJ, et al: Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet 2000;355:1781-1785.
37. Feng J, Yan J, Buzin CH, Sommer SS, Towbin JA: Comprehensive mu tation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol 2002;40:1120-1124.
38. Hoffman EP, Brown RH, Kunkel LM: Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
39. Campbell KP: Three muscular dystrophies: Loss of cytoskeleton- extracellular matrix linkage. Cell 1995;80:675-679.
40. Lapidos KA, Kakkar R, McNally EM: The dystrophin glycoprotein complex: Signaling strength and integrity for the sarcolemma. Circ Res 2004;94:1023-1031.
41. Nishino I, Ozawa E: Muscular dystrophies. Curr Opin Neurol 2002;15:539-544.
42. Ozawa E, Yoshida M, Suzuki A, Mizuno Y, Hagiwara Y, Noguchi S: Dystrophin-associated proteins in muscular dystrophy. Hum Mol Genet 1995;4:1711-1716.
43. Dalkilic I, Kunkel LM: Muscular dystrophies: Genes to pathogenesis. Curr Opin Genet Dev 2003;13:231-238.
44. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG: Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005;15:1921-1933.
45. Torelli S, Brown SC, Jimenez-Mallebrera C, Geng L, Muntoni F, Sewry CA: Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004;30:540-545.
46. Sander M, Chavoshan B, Harris SA, Iannacoone ST, Stull JT, Thomas GD, Victor RG: Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2000;97:13818-13823.
47. Chang WJ, Iannaccone ST, Lau KS, et al: Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA 1996;93:9142-9147.
48. Koenig M, Hoffman EP, Bertelson CJ, et al: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-517.
49. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA: Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799-2804.
50. Nonaka I: Animal models of muscular dystrophies. Lab Anim Sci 1998;48:8-17.
51. Collins CA, Morgan JE: Duchenne's muscular dystrophy: Animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003;84:165-172.
52. Durbeej M, Campbell KP: Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 2002;12:349-361.
53. Heydemann A, McNally EM: Regenerating more than muscle in muscular dystrophy. Circulation 2004;110:3290-3292.
54. Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO: Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res 1993;72:349-360.
55. Emery AE: The muscular dystrophies. Lancet 2002;359:687-695.
56. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeny HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993;90:3710-3714.
57. Lynch GS: Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophy. Clin Exp Pharmacol Physiol 2004;31:557-561.
58. Kumar A, Khanadelwal N, Malya R, Reid MB, Boriek AM: Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004;18:102-113.
59. Bowles NE, Bowles KR, Towbin JA: The "Final Common Pathway" hypothesis and inherited cardiovascular disease: The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000;25:168-175.
60. Badorff C, Lee GH, Lamphear BJ, et al: Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999;5:320-326.
61. Xiong D, Lee GH, Badorff C, et al: Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med 2002;8:872-877.
62. Kass S, MacRae C, Graber HL, et al: A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet 1994;7:546-551.
63. Fatkin D, MacRae C, Sasaki T, et al: Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;34:1715-1724.
64. Graber HL, Unverferth DV, Baker PB, Ryan JM, Baba N, Wooley CF: Evolution of hereditary cardiac conduction and muscle disorder: A study involving a family with 6 generations affected. Circulation 1986;74:21-35.
65. Ahmad F, Seidman JG, Seidman CE: The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185-216.
66. Towbin JA, Solaro RJ: Genetics of dilated cardiomyopathy: More genes that kill. J Am Coll Cardiol 2004;44:2041-2043.
67. Fatkin D, Graham RM: Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002;82:945-980.
68. Tsubata S, Bowles KR, Vatta M, et al: Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000;106:655-662.
69. Mohapatra B, Jimenez S, Lin JH, et al: Mutations in the muscle LIM protein and α-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003;80:207-215.
70. Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT: Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-752.
71. Li D, Tapscott T, Gonzalez O, et al: Desmin mutations responsible for idiopathic dilated cardiomyopathy. Circulation 1999;100:461-464.
72. Kamisago M, Sharma SD, DePalma SR, et al: Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-1696.
73. Gerul B, Gramlich M, Atherton J, et al: Mutations of TTN encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002;30:201-204.
74. Olson TM, Illenberger S, Kishimoto NY, Huttelmaier S, Keating MT, Jockusch BM: Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002;105:431-437.
75. Regitz-Zagrosek V, Daehmlow S, Knueppel T, et al: Novel mutations in the β-myosin heavy chain and myosin binding protein C gene are associated with dilated cardiomyopathy. Circulation 2001;104(Suppl II):II-572.
76. Olson TM, Kishimoto NY, Whitby FG, Michels W: Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001;33:723-732.
77. Schmitt JP, Kamisago M, Asahi M, et al: Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003;299:1410-1413.
78. Ozawa E, Mizuno Y, Hagiward Y, Sasaoka T, Yoshida M: Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 2005;32:563-576.
79. Wheeler MT, McNally EM: Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med 2003;13:238-243.
80. Coral-Vazquez R, Cohn RD, Moore SA, et al: Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999;98:465-474.
81. Wheeler MT, Allikian MJ, Heydemann A, Hadhazy M, Zarnegar S, McNally EM: Smooth muscle cell-extrinsic vascular spasms arise from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest 2004;113:668-675.
82. Nigro V, Okazaki Y, Belsito A, et al: Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-607.
83. Sakamoto A, Ono K, Abe M, et al: Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997;94:13873-13878.
84. Sakamoto A, Abe M, Masaki T: Delineation of genomic deletion in cardiomyopathic hamster. FEBS Lett 1999;447:124-128.
85. Jung D, Duclos F, Apostal B, et al: Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy. J Biol Chem 1996;271:32321-32329.
86. Nigro V, de Sa Moreira E, Piluso G, et al: Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 1996;14:195-198.
87. Witt S, Zieseniss A, Fock U, Jockusch BM, Illenberger S: Comparative biochemical analysis suggests that vinculin and metavinculin cooperate in muscular adhesion sites. J Biol Chem 2004;279:31533-31543.
88. Maeda M, Holder E, Lowes B, Valent S, Bies RD: Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 1997;95:17-20.
89. Broderick MJ, Winder SJ: Spectirn, alpha-actinin, and dystrophin. Adv Protein Chem 2005;70:203-246.
90. Haghighi K, Kolokathis F, Pater L, et al: Human phospholamban null results in lethal diliated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003;111:869-876.
91. Murphy RT, Mogensen J, Shaw A, et al: Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 2004;363:371-372.
92. Pyle WG, Solaro RJ: At the crossroads of myocardial signaling: The role of Z-discs in intracellular signaling and cardiac function. Circ Res 2004;94:296-305.
93. Knoll R, Hoshijima M, Hoffman HM, et al: The cardiac mechanical stretch sensor machinery involves a Z-disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002;11:943-955.
94. Arber S, Hunter JJ, Ross J Jr, et al: MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997;88:393-403.
95. Zolk O, Caroni P, Bohm M: Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation 2000;101:2674-2677.
96. Katz AM: Cytoskeletal abnormalities in the failing heart. Out on a LIM? Circulation 2000;101:2672-2673.
97. Vatta M, Mohapatra B, Jimenez S, et al: Mutations in cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003;42:2014-2027.
98. Zhou Q, Chu PH, Huang C, et al: Ablation of cyipher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol 2001;155:605-612.
99. Arimura T, Hayashi T, Terada H, Lee SW, Zhou Q, Takahashi M, Ueda K, Nouchi T, Hohda S, Shibutani M, Hirose M, Chen J, Park JE, Yasunami M, Hayashi H, Kimura A: A cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol Chem 2004;279:6746-6752.
100. Granzier H, Labeit S: The grant protein titin: A major player in myocardial mechanics, signaling, and disease. Circ Res 2004;94:284-295.
101. Jung M, Poepping I, Perrot A, Ellmer AE, Wienker TF, Dietz R, Reis A, Oserziel KJ: Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel ocus on chromosomes 2q14-q22. Am J Hum Genet 1999;65:1068-1077.
102. Olson TM, Keating MT: Mapping a cardiomyopathy locus to chromosome 3p22-p25. J Clin Invest 1996;97:528-532.
103. Messina DN, Speer MC, Pericak-Vance MA, McNally EM: Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997;61:909-917.
104. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L: Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000;101:473-476.
105. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, DiLenarda A, Bohlmeyer TJ, Ferguson DA, Brodsky GL, Boucek MM, Lascor J, Moss AC, Li WL, Stetler GL, Muntoni F, Bristow MR, Mestroni L, Familial Dilated Cardiomyopathy Registry Research Group. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003;41:771-780.
106. Stuurman N, Heins S, Aebi U: Nuclear lamins: Their structure, assembly and interactions. J Struct Biol 1998;122:42-66.
107. Worman HJ: Components of the nuclear envelope and their role in human disease. Novartis Found Symp 2005;264:35-42.
108. Ben Yaou R, Muchir A, Arimura T, Massart C, Demay L, Richard P, Bonne G: Genetics of laminopathies. Novartis Found Symp 2005;164:81-90.
109. Bonne G, DiBarletta MR, Varnous S, et al: Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21: 285-288.
110. Di Barletta R, Ricci E, Galluzzi G, et al: Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000;66:1407-1412.
111. Muchir A, Bonne G, van der Kooi AJ, et al: Identification of mutations in the gene encoding lamin A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbance (LGMD1B). Hum Mol Genet 2000;9:1453-1459.
112. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, Kesteven SH, Michalicek J, Otway R, Verheyen F, Rainer S, Stewart CL, Martin D, Feneley MP, Fatkin D: Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 2004;113:357-369.
113. Novak KJ, Wattanasikichaigood D, Goebel HH, et al: Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet 1999;23:208-212.
114. Goldfarb LG, Park K-Y, Cervenakova L, et al: Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998;19:402-403.
115. Dalakas MC, Park K-Y, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG: Desmin myopathy a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-780.
116. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D: A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet 1996;12:385-389.
117. Barth PG, Scholte HR, Berden JA, et al: An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. J Neurol Sci 1983;62:327-355.
118. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR: Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nature Cell Biol 1999;1:215-220.
119. Selcen D, Engel AG: Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann Neurol 2005;57:269-276.
120. Agrawal PB, Strickland CD, Midgett C, Morales A, Newburger DE, Poulos MA, Tomczak KK, Ryan MM, Iannaccone ST, Crawford TO, Laing NG, Beggs AH: Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol 2004;56:86-96.
121. Hackman P, Vihola A, Haravuori H, et al: Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the grant skeletal muscle protein titin. Am J Hum Genet 2002;71:492-500.
122. Barresi R, Di Blasi C, Negri T, et al: Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 2000;37:102-107.
123. Garvey SM, Rajan C, Lerner AP, Frankel WN, Cox GA: The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomics 2002;79:146-149.
124. Milner DJ, Weitzer G, Tran D, Bradley A, Capetanaki Y: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 1996;134:1255-1270.
125. Badorff C, Knowlton KU: Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: From bench to bedside. Med Microbiol Immunol (Berl) 2004;193:121-126.
126. Vatta M, Stetson SJ, Perez-Verdra A, et al: Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal for patients on assist device therapy. Lancet 2000;359:936-941.
127. Vatta M, Stetson SJ, Jimenez S, et al: Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol 2004;43:811-817.